NICE and NHS England launched a consultation in Autumn 2016 on changes proposed to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s Technology Appraisal (TA) and Highly Specialised Technologies (HST) programmes.
We argued that the NHS needs to become more adept at phasing in new treatments and technologies that are proven to be cost-effective, and disinvesting in outdated lower-value activities.
We also recognised that introducing new technologies can cause disruption to existing services but in times of financial constraint the need to encourage innovation, and shift resources to higher-value activities, is even more urgent.
Furthermore, we argued if the NHS has to prioritise new technologies in a period of financial constraint it should prioritise treatments and technologies by their relative cost-effectiveness, rather than their budgetary impact.
You might also like...
New polling data with Ipsos MORI reveal UK public’s awareness of and attitudes towards the planned...
Data is telling a horrifying story about the toll that the pandemic is taking. It’s also playing a...
Health Foundation response to the NHS Net Zero Expert Panel consultation on how the NHS can continue...
Health Foundation @HealthFdn
RT @CreinaLilburne: "One of the big issues at the moment is the NHS's approach to risk... How much local decision-making can the NHS tolera…Follow us on Twitter
Work with us
We look for talented and passionate individuals as everyone at the Health Foundation has an important role to play.View current vacancies
The Q community
Q is an initiative connecting people with improvement expertise across the UK.Find out more